Fundraising FoxKALA BIO
NASDAQ: KALAArlington, US · Founded 2009 · Delaware corporation · 7 known investors
Find your way into KALA BIO
Each arrow is one introduction. Sign up to fill in the first one.
Ask Nicole Gaudelli to introduce you to Justin Hanes
You →Nicole · together at Johns Hopkins University →Justin
Ask Jamie Chen to introduce you to MARK IWICKI
You →Jamie · together at Civitas Therapeutics →MARK
Ask Sam Okafor to introduce you to Todd Bazemore
You →Sam · together at Dyax →Todd
Sign up to find every way you can get introduced to KALA BIO
- Your email: who you already know at KALA BIO, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the KALA BIO team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
Founders & leadership
KALA BIO was founded in 2009 by Justin Hanes and Kevin Pojasek.
Investors · 7
How we know: Longitude Capital's portfolio page · the S-1 prospectus · the VCSheet dataset · Not right? Tell us
How we know: SR One Capital Management's portfolio page · Not right? Tell us
How we know: Ysios Capital's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$148M disclosed across 9 of 13 rounds · 1900–2026
▶$1.8MraisedMar 2026 · 1 investors · PharmaceuticalsRule 506(b)
- Yonatan ColmanDirector
- Brendan PurdyDirector
- Chaim BergerDirector
- Avi MinkowitzExecutive Officer, Director
- Hillel PosenDirector
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- Minimum investment
- $1.8M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedFeb 2026 · 20 investors · BiotechnologyRule 506(b)
- CHAIM BERGERDirector
- HILLEL POSENDirector
- AVI MINKOWITZExecutive Officer, Director
- DAVID LAZARDirector
- BRENDAN PURDYDirector
- YONATAN COLMANDirector
- Offering amount
- $4.2M
- Amount sold
- $2.3M
- Minimum investment
- $44.9K
- Sales commissions
- $39K
- Placement agents
- FM Global Markets Inc.
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.7MraisedDec 2024 · 6 investors · BiotechnologyRule 506(b)
- Darius KharabiExecutive Officer
- Todd BazemoreExecutive Officer
- Gregory D. PerryDirector
- Marjan FaridDirector
- Andrew I. KovenDirector
- Howard B. RosenDirector
- Mark IwickiExecutive Officer, Director
- Mary ReumuthExecutive Officer
- C. Daniel MyersDirector
- Kim BrazzellExecutive Officer
- Offering amount
- $10.7M
- Amount sold
- $10.7M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.5MraisedJun 2024 · 5 investors · BiotechnologyRule 506(b)
- Mark IwickiExecutive Officer, Director
- Kim BrazzellExecutive Officer
- Marjan FaridDirector
- Todd BazemoreExecutive Officer
- Mark S. BlumenkranzDirector
- Mary ReumuthExecutive Officer
- C. Daniel MyersDirector
- Darius KharabiExecutive Officer
- Gregory D. PerryDirector
- Andrew I. KovenDirector
- Howard B. RosenDirector
- Offering amount
- $12.5M
- Amount sold
- $12.5M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.1MraisedNov 2021 · 26 investors · BiotechnologyRule 506(b)
- Kim BrazzellExecutive Officer
- Gregory D. PerryDirector
- Mary ReumuthExecutive Officer
- Mark S. BlumenkranzDirector
- Andrew KovenDirector
- Darius KharabiExecutive Officer
- Howard B. RosenDirector
- Gregory GrunbergDirector
- Mark IwickiExecutive Officer, Director
- Hongming ChenExecutive Officer
- Robert PaullDirector
- Eric L. TrachtenbergExecutive Officer
- C. Daniel MyersDirector
- Todd BazemoreExecutive Officer
- Offering amount
- $36.5M
- Amount sold
- $16.1M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$67.9MraisedApr 2016 · 25 investors · BiotechnologyRule 506(b)
- Kevin BittermanDirector
- Chen YuDirector
- Kim BrazzellExecutive Officer
- Charles McDermottExecutive Officer
- Robert TepperDirector
- Robert LangerDirector
- Robert PaullDirector
- Mark IwickiExecutive Officer, Director
- Greg GrunbergDirector
- Rajeev ShahDirector
- Howard B. RosenDirector
- Hongming ChenExecutive Officer
- Offering amount
- $67.9M
- Amount sold
- $67.9M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedAug 2015 · 1 investors · BiotechnologyRule 506(b)
- Charles McDermottExecutive Officer
- Kevin BittermanDirector
- Robert TepperDirector
- Robert PaullDirector
- Kim BrazzellExecutive Officer
- Howard B. RosenDirector
- Karen WagnerDirector
- Mark IwickiExecutive Officer, Director
- Rajeev ShahDirector
- Robert LangerDirector
- Hongming ChenExecutive Officer
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$22.5MraisedApr 2014 · 16 investors · BiotechnologyRule 506(b)
- Robert TepperDirector
- Kevin BittermanDirector
- Robert PaullDirector
- Kim BrazzellExecutive Officer
- Howard B. RosenDirector
- Guillaume PfeferExecutive Officer, Director
- Bernard GillyDirector
- Robert LangerDirector
- Offering amount
- $22.5M
- Amount sold
- $22.5M
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
3 people who came through KALA BIO went on to found or lead other companies.
Related companies · 2
Companies working in the same space as KALA BIO.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $255.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $180.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does KALA BIO do?
- A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
- Who founded KALA BIO?
- KALA BIO was founded by Justin Hanes, Kevin Pojasek in 2009.
- Who are KALA BIO's investors?
- KALA BIO's investors include Longitude Capital, SR One Capital Management, Ysios Capital, Atlas Venture, Lux Capital, RA Capital, Third Rock Ventures.
- How much funding has KALA BIO raised?
- KALA BIO has disclosed $148M raised across 9 of its 13 known rounds.
- Where is KALA BIO headquartered?
- KALA BIO is headquartered in Arlington, US.